RRx-001, A novel dinitroazetidine radiosensitizer

Bryan Oronsky, Jan Scicinski, Shoucheng Ning, Donna Peehl, Arnold Oronsky, Pedro Cabrales, Mark Bednarski, Susan Knox

Research output: Contribution to journalReview article

Abstract

The ‘holy grail’ in radiation oncology is to improve the outcome of radiation therapy (RT) with a radiosensitizer—a systemic chemical/biochemical agent that additively or synergistically sensitizes tumor cells to radiation in the absence of significant toxicity. Similar to the oxygen effect, in which DNA bases modified by reactive oxygen species prevent repair of the cellular radiation damage, these compounds in general magnify free radical formation, leading to the permanent “fixation” of the resultant chemical change in the DNA structure. The purpose of this review is to present the origin story of the radiosensitizer, RRx-001, which emerged from the aerospace industry. The activity of RRx-001 as a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia, are the subject of future reviews.

Original languageEnglish (US)
Pages (from-to)371-377
Number of pages7
JournalInvestigational New Drugs
Volume34
Issue number3
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Fingerprint

Radiation
Radiation Oncology
Hemorrhagic Shock
DNA
Sickle Cell Anemia
Malaria
Free Radicals
Reactive Oxygen Species
Neoplasms
Industry
Radiotherapy
Oxygen
RRx-001

Keywords

  • Cancer
  • Chemosensitizer
  • Clinical trials
  • Radiosensitization
  • Radiosensitizer
  • RRx-001

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

Oronsky, B., Scicinski, J., Ning, S., Peehl, D., Oronsky, A., Cabrales, P., ... Knox, S. (2016). RRx-001, A novel dinitroazetidine radiosensitizer. Investigational New Drugs, 34(3), 371-377. https://doi.org/10.1007/s10637-016-0326-y

RRx-001, A novel dinitroazetidine radiosensitizer. / Oronsky, Bryan; Scicinski, Jan; Ning, Shoucheng; Peehl, Donna; Oronsky, Arnold; Cabrales, Pedro; Bednarski, Mark; Knox, Susan.

In: Investigational New Drugs, Vol. 34, No. 3, 01.06.2016, p. 371-377.

Research output: Contribution to journalReview article

Oronsky, B, Scicinski, J, Ning, S, Peehl, D, Oronsky, A, Cabrales, P, Bednarski, M & Knox, S 2016, 'RRx-001, A novel dinitroazetidine radiosensitizer', Investigational New Drugs, vol. 34, no. 3, pp. 371-377. https://doi.org/10.1007/s10637-016-0326-y
Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P et al. RRx-001, A novel dinitroazetidine radiosensitizer. Investigational New Drugs. 2016 Jun 1;34(3):371-377. https://doi.org/10.1007/s10637-016-0326-y
Oronsky, Bryan ; Scicinski, Jan ; Ning, Shoucheng ; Peehl, Donna ; Oronsky, Arnold ; Cabrales, Pedro ; Bednarski, Mark ; Knox, Susan. / RRx-001, A novel dinitroazetidine radiosensitizer. In: Investigational New Drugs. 2016 ; Vol. 34, No. 3. pp. 371-377.
@article{fc292d25a35948f68519c7519cafd9d2,
title = "RRx-001, A novel dinitroazetidine radiosensitizer",
abstract = "The ‘holy grail’ in radiation oncology is to improve the outcome of radiation therapy (RT) with a radiosensitizer—a systemic chemical/biochemical agent that additively or synergistically sensitizes tumor cells to radiation in the absence of significant toxicity. Similar to the oxygen effect, in which DNA bases modified by reactive oxygen species prevent repair of the cellular radiation damage, these compounds in general magnify free radical formation, leading to the permanent “fixation” of the resultant chemical change in the DNA structure. The purpose of this review is to present the origin story of the radiosensitizer, RRx-001, which emerged from the aerospace industry. The activity of RRx-001 as a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia, are the subject of future reviews.",
keywords = "Cancer, Chemosensitizer, Clinical trials, Radiosensitization, Radiosensitizer, RRx-001",
author = "Bryan Oronsky and Jan Scicinski and Shoucheng Ning and Donna Peehl and Arnold Oronsky and Pedro Cabrales and Mark Bednarski and Susan Knox",
year = "2016",
month = "6",
day = "1",
doi = "10.1007/s10637-016-0326-y",
language = "English (US)",
volume = "34",
pages = "371--377",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - RRx-001, A novel dinitroazetidine radiosensitizer

AU - Oronsky, Bryan

AU - Scicinski, Jan

AU - Ning, Shoucheng

AU - Peehl, Donna

AU - Oronsky, Arnold

AU - Cabrales, Pedro

AU - Bednarski, Mark

AU - Knox, Susan

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The ‘holy grail’ in radiation oncology is to improve the outcome of radiation therapy (RT) with a radiosensitizer—a systemic chemical/biochemical agent that additively or synergistically sensitizes tumor cells to radiation in the absence of significant toxicity. Similar to the oxygen effect, in which DNA bases modified by reactive oxygen species prevent repair of the cellular radiation damage, these compounds in general magnify free radical formation, leading to the permanent “fixation” of the resultant chemical change in the DNA structure. The purpose of this review is to present the origin story of the radiosensitizer, RRx-001, which emerged from the aerospace industry. The activity of RRx-001 as a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia, are the subject of future reviews.

AB - The ‘holy grail’ in radiation oncology is to improve the outcome of radiation therapy (RT) with a radiosensitizer—a systemic chemical/biochemical agent that additively or synergistically sensitizes tumor cells to radiation in the absence of significant toxicity. Similar to the oxygen effect, in which DNA bases modified by reactive oxygen species prevent repair of the cellular radiation damage, these compounds in general magnify free radical formation, leading to the permanent “fixation” of the resultant chemical change in the DNA structure. The purpose of this review is to present the origin story of the radiosensitizer, RRx-001, which emerged from the aerospace industry. The activity of RRx-001 as a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia, are the subject of future reviews.

KW - Cancer

KW - Chemosensitizer

KW - Clinical trials

KW - Radiosensitization

KW - Radiosensitizer

KW - RRx-001

UR - http://www.scopus.com/inward/record.url?scp=84957597272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957597272&partnerID=8YFLogxK

U2 - 10.1007/s10637-016-0326-y

DO - 10.1007/s10637-016-0326-y

M3 - Review article

C2 - 26841903

AN - SCOPUS:84957597272

VL - 34

SP - 371

EP - 377

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -